Frovatriptan Succinate
4 NDCs across 4 manufacturers|3 Generic,1 Brand
Frovatriptan Succinate is used to treat migraine disorders, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
The brand product was first FDA-approved on Nov 8, 2001, and the first generic was approved Aug 28, 2014. FDA's Orange Book lists 4 AB-rated (therapeutically equivalent) products for this ingredient. In 2024, Medicare Part D spent $3 million on Frovatriptan Succinate across 8,298 claims for 2,097 beneficiaries.
Frovatriptan Succinate is available as 4 NDCs from 4 manufacturers (3 generic, 1 brand), with NADAC prices from $2.72 to $149.50 per EA — the most expensive product costs about 55× the cheapest. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
4
3G / 1B
Manufacturers
4
competing in market
Price Spread
$2.72 – $149.50
per EA
7d Activity
avg -2.3% WoW · of 4 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Explore this market from other angles
Move from the molecule page into the supplier, class, and trend views that create the strongest internal-link cluster for this market.
Top supplier
Endo USA Inc. manufacturer profile
Open the supplier page for the manufacturer with the strongest footprint in this market.
Lead class
Serotonin-1b and Serotonin-1d Receptor Agonist class view
See how this market rolls up into the broader therapeutic class and compare other drugs in the same bucket.
Trend hub
Latest market trends
Move from this single molecule into the current cross-market mover and volatility view.
Guide
How to interpret NADAC
Review the benchmark methodology behind the prices and spreads shown on this market page.
Manufacturer Breakdown
4 manufacturers producing FROVATRIPTAN SUCCINATE
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
FROVA 2.5 MG TABLET | $149.5003 per EA | — |
FROVATRIPTAN SUCC 2.5 MG TAB | $2.7171 per EA | -2.30% |
FROVATRIPTAN SUCC 2.5 MG TAB | $2.7171 per EA | -2.30% |
FROVATRIPTAN SUCC 2.5 MG TAB | $2.7171 per EA | -2.30% |
Frequently Asked Questions
What is Frovatriptan Succinate used to treat?
Frovatriptan Succinate is used to treat migraine disorders, per the National Library of Medicine's MED-RT classification.
When did Frovatriptan Succinate become available as a generic?
FDA approved the first generic Frovatriptan Succinate (ANDA) on Aug 28, 2014. The Orange Book currently lists 4 AB-rated products for this ingredient, meaning FDA considers them therapeutically equivalent to the brand.
How much does Medicare spend on Frovatriptan Succinate?
In 2024, Medicare Part D spent $3 million on Frovatriptan Succinate across 8,298 claims for 2,097 beneficiaries.
How many Frovatriptan Succinate products are on the market?
The Frovatriptan Succinate drug market contains 4 NDCs from 4 manufacturers — 3 generic and 1 brand product.
What is the price range for Frovatriptan Succinate?
NADAC reference prices for Frovatriptan Succinate range from $2.7171 to $149.5003 per EA — the most expensive product costs about 55× the cheapest.
Is generic Frovatriptan Succinate cheaper than brand?
The average generic NADAC for Frovatriptan Succinate is $2.7171 per EA, versus $149.5003 for brand-labeled products — brand versions average about 55× the generic price.
Which manufacturers make Frovatriptan Succinate?
4 manufacturers list Frovatriptan Succinate in NADAC. Ranked by number of NDCs, the largest are Endo USA Inc. (1), Ingenus Pharmaceuticals LLC (1), Glenmark Pharmaceuticals Inc., USA (1), Amneal Pharmaceuticals NY LLC (1).
How has the price of Frovatriptan Succinate changed recently?
Over the past 7 days, 0 Frovatriptan Succinate NDCs rose and 3 fell, with a market-wide average change of -2.3%.